Dyne Therapeutics price target cut to $30 from $35 at RBC Capital
RBC Capital cut its Dyne Therapeutics price target to $30.00 per share from $35.00, according to a Benzinga ratings action roundup.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.